Olivier Taelman serves as the Chief Executive Officer of Nyxoah, having assumed leadership of the medical technology enterprise. With extensive executive experience across global medtech and healthcare sectors, he directs the company's corporate strategy, clinical trial execution, regulatory submissions, and international commercialization efforts for its innovative obstructive sleep apnea neurostimulation treatments.